Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells
Jihyun Lim1, Aram Lee1, Hee Gu Lee2 and Jong-Seok Lim1,3,*
1Department of Biological Science, Sookmyung Women’s University, Seoul 04310,
2Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141,
3Cellular Heterogeneity Research Center, Sookmyung Women’s University, Seoul 04310, Republic of Korea
E-mail: jslim@sookmyung.ac.kr
Tel: +82-2-710-9560, Fax: +82-2-2077-7322
Received: April 25, 2019; Revised: July 2, 2019; Accepted: July 4, 2019; Published online: August 21, 2019.
© The Korean Society of Applied Pharmacology. All rights reserved.

Abstract
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that exert suppressive function on the immune response. MDSCs expand in tumor-bearing hosts or in the tumor microenvironment and suppress T-cell responses via various mechanisms, whereas a reduction in their activities has been observed in autoimmune diseases or infections. It has been reported that the symptoms of various diseases, including malignant tumors, can be alleviated by targeting MDSCs. Moreover, MDSCs can contribute to patient resistance to therapy using immune checkpoint inhibitors. In line with these therapeutic approaches, diverse oligonucleotide-based molecules and small molecules have been evaluated for their therapeutic efficacy in several disease models via the modulation of MDSC activity. In the current review, MDSC-targeting oligonucleotides and small molecules are briefly summarized, and we highlight the immunomodulatory effects on MDSCs in a variety of disease models and the application of MDSC-targeting molecules for immuno-oncologic therapy.
Keywords: Myeloid-derived suppressor cells (MDSCs), Oligonucleotide-based molecules, Small molecules, Tumor microenvironment, Immune suppression, MDSC-targeting agents


This Article


Cited By Articles
  • CrossRef (0)

e-submission

Archives